1374213-83-8

Basic information

• Product Name: 6-(3-(4-acetylpiperazin-1-yl)phenylamino)-4-(1-phenylcyclopropylamino)nicotinamide
• Synonyms: 6-(3-(4-acetylpiperazin-1-yl)phenylamino)-4-(1-phenylcyclopropylamino)nicotinamide
• CAS NO: 1374213-83-8
• Molecular Weight: 470.574
• Mol File: 1374213-83-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 6-(3-(4-acetylpiperazin-1-yl)phenylamino)-4-(1-phenylcyclopropylamino)nicotinamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(3-(4-acetylpiperazin-1-yl)phenylamino)-4-(1-phenylcyclopropylamino)nicotinamide(1374213-83-8)
• EPA Substance Registry System: 6-(3-(4-acetylpiperazin-1-yl)phenylamino)-4-(1-phenylcyclopropylamino)nicotinamide(1374213-83-8)

Safety Data

• Hazardous Substances Data: 1374213-83-8(Hazardous Substances Data)

Upstream product

• 1374215-15-2 6-chloro-4-(1-phenylcyclopropylamino)nicotinamide 
• 41049-53-0 1-phenylcyclopropylamine 
• 70593-57-6 4,6-dichloro-nicotinamide 
• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 5466-62-6 4,6-dihydroxy-nicotinic acid 
• 73027-79-9 4,6-dichloro-nicotinic acid 
• 206879-72-3 4-(3-amino-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 206879-94-9 4-(3-nitro-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 100-47-0 benzonitrile 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 1374213-82-7 4-(1-phenylcyclopropylamino)-6-(3-(piperazin-1-yl)phenylamino)nicotinamide 
• 108-24-7 acetic anhydride 

Relevant articles and documents

NICOTINAMIDES AS JAK KINASE MODULATORS

The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.